False Claims Act liability for off-label promotion of pharmaceutical products

Greene

Stephanie M.

Greene, Stephanie M.

Dept. of Business Law, Carroll School of Management

Author

text

article

2005 2005 monographic

2005

monographic

English eng

English

eng

electronic application/pdf digitized other analog

electronic

application/pdf

digitized other analog

This article details pharmaceutical company liability for off-label promotional marketing strategies. Despite near record revenues, the pharmaceutical industry faces struggles relating its business cycle of research, development, patenting and then inevitable competition from generics. This boom-bust scenario forced companies to seek profits from both increased marketing and through expanding the markets for their drugs. The twin phenomena of direct-to-consumer advertising and off-label promotions prompted regulatory action and resulting in legislation of the False Claims Act. The author reviews pharmaceutical tactics that have triggered review by the government, and concludes with recommendations on compliance and best practices for pharmaceutical companies.

Version of record.

Electronic reproduction. Chestnut Hill, Mass. : University Libraries, Boston College, 2009.

Penn State Law Review 1545-7877 110 1 41 68 pp. 41-68 2005

Penn State Law Review

1545-7877

110 1 41 68 pp. 41-68 2005

110

41 68 pp. 41-68

pp. 41-68

2005

Use of this resource is governed by the terms and conditions of the Creative Commons "Attribution-Noncommercial-No Derivative Works 3.0 United States" (http://creativecommons.org/licenses/by-nc-nd/3.0/us/)

Business Law PennStateLR-v110-Greene-p41.pdf PennStateLR-v110-Greene-permissions.pdf ThumbnailCoverImage00473.jpg

Business Law

PennStateLR-v110-Greene-p41.pdf

PennStateLR-v110-Greene-permissions.pdf

ThumbnailCoverImage00473.jpg

MChB English eng

MChB

English eng

English

eng